ESSA Pharma Inc. (EPIX) Given $5.10 Average Price Target by Analysts

ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) has been given a consensus broker rating score of 1.67 (Buy) from the three brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company. ESSA Pharma’s rating score has declined by 67% from three months ago as a result of a number of analysts’ ratings changes.

Analysts have set a 1-year consensus price objective of $5.10 for the company, according to Zacks. Zacks has also given ESSA Pharma an industry rank of 103 out of 265 based on the ratings given to related companies.

A number of analysts have recently issued reports on the stock. Zacks Investment Research cut shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, September 12th. Bloom Burton cut shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, September 12th.

ESSA Pharma (NASDAQ EPIX) opened at $0.25 on Friday. ESSA Pharma has a 1-year low of $0.24 and a 1-year high of $3.59. The company has a debt-to-equity ratio of -3.00, a current ratio of 2.32 and a quick ratio of 2.32.

COPYRIGHT VIOLATION WARNING: “ESSA Pharma Inc. (EPIX) Given $5.10 Average Price Target by Analysts” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/12/11/essa-pharma-inc-epix-given-5-10-average-price-target-by-analysts.html.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply